GB9009549D0 - Recombinant antibody and method - Google Patents

Recombinant antibody and method

Info

Publication number
GB9009549D0
GB9009549D0 GB909009549A GB9009549A GB9009549D0 GB 9009549 D0 GB9009549 D0 GB 9009549D0 GB 909009549 A GB909009549 A GB 909009549A GB 9009549 A GB9009549 A GB 9009549A GB 9009549 D0 GB9009549 D0 GB 9009549D0
Authority
GB
United Kingdom
Prior art keywords
recombinant antibody
recombinant
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB909009549A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Celltech Ltd
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Priority to GB909009549A priority Critical patent/GB9009549D0/en
Publication of GB9009549D0 publication Critical patent/GB9009549D0/en
Priority to CA002081478A priority patent/CA2081478A1/en
Priority to PCT/US1991/002942 priority patent/WO1991016927A1/en
Priority to HU923371A priority patent/HUT62652A/hu
Priority to EP19910910051 priority patent/EP0528951A4/en
Priority to BR919106392A priority patent/BR9106392A/pt
Priority to AU79001/91A priority patent/AU7900191A/en
Priority to JP3509384A priority patent/JPH06500229A/ja
Priority to NO92924087A priority patent/NO924087L/no
Priority to FI924818A priority patent/FI924818A/fi
Priority to HU9203371A priority patent/HU9203371D0/hu
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
GB909009549A 1990-04-27 1990-04-27 Recombinant antibody and method Pending GB9009549D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GB909009549A GB9009549D0 (en) 1990-04-27 1990-04-27 Recombinant antibody and method
JP3509384A JPH06500229A (ja) 1990-04-27 1991-04-29 擬人化ｃｄｒ移植抗ｉｃａｍ―１抗体、その生産方法及びその使用
EP19910910051 EP0528951A4 (en) 1990-04-27 1991-04-29 Humanized cdr-grafted anti-icam-1 antibodies, methods of preparation and usage thereof
PCT/US1991/002942 WO1991016927A1 (en) 1990-04-27 1991-04-29 Humanized cdr-grafted anti-icam-1 antibodies, methods of preparation and usage thereof
HU923371A HUT62652A (en) 1990-04-27 1991-04-29 Process for producing humqnized cdr-inoculated anti-icam-1 antibodies
CA002081478A CA2081478A1 (en) 1990-04-27 1991-04-29 Humanized cdr-grafted anti-icam-1 antibodies, methods of preparation and usage thereof
BR919106392A BR9106392A (pt) 1990-04-27 1991-04-29 Anticorpos anti-icam-1 enxertados-cdr humanizados,metodos de preparacao e uso dos mesmos
AU79001/91A AU7900191A (en) 1990-04-27 1991-04-29 Humanized cdr-grafted anti-icam-1 antibodies, methods of preparation and usage thereof
NO92924087A NO924087L (no) 1990-04-27 1992-10-22 Antistoffer, fremgangsmaate for deres fremstilling og anvendelse dera
FI924818A FI924818A (fi) 1990-04-27 1992-10-23 Cdr-ympade anti-icam-1-antikroppar foer maenniskobruk, foerfaranden foer deras framstaellning samt deras anvaendning
HU9203371A HU9203371D0 (en) 1990-04-27 1992-10-27 Humanized cdr-grafted anti-icam-1 antibodies and method for producing them5

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909009549A GB9009549D0 (en) 1990-04-27 1990-04-27 Recombinant antibody and method

Publications (1)

Publication Number Publication Date
GB9009549D0 true GB9009549D0 (en) 1990-06-20

Family

ID=10675134

Family Applications (1)

Application Number Title Priority Date Filing Date
GB909009549A Pending GB9009549D0 (en) 1990-04-27 1990-04-27 Recombinant antibody and method

Country Status (8)

Country Link
EP (1) EP0528951A4 (ja)
JP (1) JPH06500229A (ja)
AU (1) AU7900191A (ja)
BR (1) BR9106392A (ja)
CA (1) CA2081478A1 (ja)
GB (1) GB9009549D0 (ja)
HU (2) HUT62652A (ja)
WO (1) WO1991016927A1 (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
EP0459577A3 (en) * 1990-06-01 1992-08-05 Merck & Co. Inc. Microbially expressed portions of a monoclonal antibody block rhinovirus attachment to cell receptors
US5871733A (en) * 1990-07-20 1999-02-16 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US5674982A (en) * 1990-07-20 1997-10-07 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5223396A (en) * 1991-05-03 1993-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. Method for detecting organ transplant rejection
JPH07502727A (ja) * 1991-10-01 1995-03-23 ザ・ジエネラル・ホスピタル・コーポレーシヨン 接着分子に対する抗体を用いた同種移植片拒絶の防止
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
WO1994004188A1 (en) * 1992-08-21 1994-03-03 Genentech, Inc. Method for treating an lfa-1-mediated disorder
WO1994007921A1 (en) * 1992-09-25 1994-04-14 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US20020081294A1 (en) 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
US6670321B1 (en) 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
EP1163003B1 (en) 1999-03-19 2009-08-12 Genentech, Inc. Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist
AU777241B2 (en) * 1999-06-24 2004-10-07 Johns Hopkins University, The Compositions and methods for preventing transepithelial transmission of HIV
US20030158382A1 (en) 2000-04-21 2003-08-21 Nobutaka Wakamiya Novel collectins
CA2478833C (en) * 2002-03-13 2015-11-10 Biogen, Inc. Anti-.alpha.v.beta.6 antibodies
CA2568570A1 (en) 2004-06-09 2005-12-29 Genentech, Inc. Method of treating granuloma annulare or sarcoid
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
JP5890017B2 (ja) * 2011-07-05 2016-03-22 ダイノナ インコーポレーテッド 抗原特異的ｔ細胞寛容を誘導する抗体およびその使用
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
KR102063341B1 (ko) * 2018-12-31 2020-01-07 다이노나(주) Icam-1에 특이적으로 결합하는 항체 및 그의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
EP0314863B1 (en) * 1987-11-02 1994-12-07 Baylor College Of Medicine Use of ICAM-1 or its functional derivatives for the treatment of non-specific inflammation

Also Published As

Publication number Publication date
EP0528951A4 (en) 1993-05-26
EP0528951A1 (en) 1993-03-03
BR9106392A (pt) 1993-04-27
HUT62652A (en) 1993-05-28
AU7900191A (en) 1991-11-27
HU9203371D0 (en) 1993-01-28
JPH06500229A (ja) 1994-01-13
CA2081478A1 (en) 1991-10-28
WO1991016927A1 (en) 1991-11-14

Similar Documents

Publication Publication Date Title
GB9009549D0 (en) Recombinant antibody and method
HU9303026D0 (en) New antibodies and their application
HU9601574D0 (en) Humanized antibodies and uses thereof
GB9415380D0 (en) Recombinant antibodies specific for tnf-
GB9013410D0 (en) Polypeptide and its use
EP0451848A3 (en) Immunoassay element and process for immunoassay
IL87730A0 (en) Peptides and antibodies
EP0285511A3 (en) Monoclonal antibodies and their uses
IL94141A (en) Laser-warning method and laser-warning arrangement
GB8921227D0 (en) Antibodies and proteins
GB9000802D0 (en) Bonding method and assembly for use therein
EP0458475A3 (en) Transpeptidation reagent and method
GB9223676D0 (en) Modified antibodies
GB9021777D0 (en) Device and method
GB9026896D0 (en) Method and composition
AU1304892A (en) Retaining method and means
GB9225262D0 (en) Recombinant antibody molecules and method
GB9004634D0 (en) An antibody and use thereof
GB9106568D0 (en) Recombinant antigen
IE892973L (en) Antigen and immunodiagnostic method
IE891280L (en) Recombinant antibodies
GB8919485D0 (en) Novel antibody and preparative method therefor
GB9204514D0 (en) Monoclonal antibodies and their use
GB9210944D0 (en) Monoclonal antibodies and their use
GB9210930D0 (en) Monoclonal antibodies and their use